Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H10FN3O5 |
| Molecular Weight | 246.183 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1[C@H](O)[C@H](O[C@@H]1C[18F])N2C=CN=C2[N+]([O-])=O
InChI
InChIKey=LPZSRGRDVVGMMX-FJBGPTLJSA-N
InChI=1S/C8H10FN3O5/c9-3-4-5(13)6(14)7(17-4)11-2-1-10-8(11)12(15)16/h1-2,4-7,13-14H,3H2/t4-,5-,6+,7+/m1/s1/i9-1
| Molecular Formula | C8H10FN3O5 |
| Molecular Weight | 246.183 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Fluoroazomycin Arabinoside F-18 (18F-FAZA) is a radiofluorinated 2-nitroimidazole derivative with hypoxia (low oxygen)-specific tracer activity. 18F-FAZA is reduced under hypoxic conditions, forming highly reactive intermediates. In its reduced form, 18F-FAZA covalently binds to macromolecules, thereby accumulating in hypoxic cells (e.g. malignant tumors) and allowing radioisotopic imaging of these particular cells with positron emission tomography (PET). (18)F-FAZA shows superior biokinetics and is, thus, a promising PET tracer for the visualization of tumor hypoxia. Clinical evaluation of 18F-FAZA is currently ongoing, and early results have been reported for head and neck, lung, prostate, and rectal cancers.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. | 2005 Jan |
|
| PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. | 2013 Aug |
|
| Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review. | 2014 Jan |
|
| Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer. | 2015 Nov |
Sample Use Guides
Tongue cancer: Fluoroazomycin Arabinoside F-18 (18F-FAZA) will be administered via intravenous injection at a dose of 5.2 MBq/kg with a minimum dose of 200 Megabecquerel (MBq) (5.4 Millicurie (mCi)) and a maximum dose of 600 MBq (16.2 mCi) prior to positron emission tomography (PET) imaging. A single dose of oral pimonidazole capsules at a dose of 0.5 g/m2, will be taken by participants 16-20 hours prior to tumor resection surgery.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:05:06 UTC 2023
by
admin
on
Sat Dec 16 08:05:06 UTC 2023
|
| Record UNII |
UG7I3Y42PV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C62520
Created by
admin on Sat Dec 16 08:05:06 UTC 2023 , Edited by admin on Sat Dec 16 08:05:06 UTC 2023
|
PRIMARY | |||
|
UG7I3Y42PV
Created by
admin on Sat Dec 16 08:05:06 UTC 2023 , Edited by admin on Sat Dec 16 08:05:06 UTC 2023
|
PRIMARY | |||
|
DB15134
Created by
admin on Sat Dec 16 08:05:06 UTC 2023 , Edited by admin on Sat Dec 16 08:05:06 UTC 2023
|
PRIMARY | |||
|
2826728
Created by
admin on Sat Dec 16 08:05:06 UTC 2023 , Edited by admin on Sat Dec 16 08:05:06 UTC 2023
|
PRIMARY | |||
|
864084-85-5
Created by
admin on Sat Dec 16 08:05:06 UTC 2023 , Edited by admin on Sat Dec 16 08:05:06 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
